Liver cancer when caught early is highly treatable and in many cases curable yet the number of new cases in the U.S. has increased to 43% in the last 16 years while most other cancers are declining. This October during Liver Cancer Awareness Month, the Global Liver Institute is working to raise awareness for the prevention of liver cancer. This year it is estimated that 42,220 adults (30,610 men and 11,610 women) in the USwill be diagnosed with primary liver cancer, with a 5-year survival rate of only 18%.
Oncimmune Plc (LON:ONC) is a leader in the development, manufacture and marketing of personalised immunodiagnostics for the screening, detection and care of cancer. The Group has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 156,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK, Europe & Asia. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT®-Liver launched in May 2018 and further tests are in development.
